ReviewAmerican journal of cancer research2021
Cardiotoxicity of chemotherapy and targeted agents.
Review in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The potential value of quercetin for colorectal cancer: a systematic review and a meta-analysis of preclinical studies.Frontiers in pharmacology · 2025Pooled it
- Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.Frontiers in pharmacology · 2023Pooled it
- Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel, Switzerland) · 2026Review
- The Potential Protective Effects of Resveratrol Against Cabazitaxel-Induced Oxidative Stress and Cardiotoxicity in Rats.Cardiovascular toxicology · 2026Article
- A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction.Communications medicine · 2026Article
- Temporal trends in cardiac arrest and cancer-related mortality among adults in the United States, 1999-2023.Cardio-oncology (London, England) · 2026Article
- Lifestyle Medicine in Cardio-Oncology-Addressing Cardiovascular Risks From the 3 C's: Cancer, Cancer Therapies, and Conventional Risk Factors.American journal of lifestyle medicine · 2026Review
- Risk Stratification for Cardiotoxicity in Childhood Cancer Survivors: State-of-the-Art Review and a Novel Two-Step Approach.Cancers · 2025Review
- Theranostics in the management of colorectal cancer.Discover nano · 2025Review
- Bioengineered In Situ-Forming Hydrogels as Smart Drug Delivery Systems for Postoperative Breast Cancer Immunotherapy: From Material Innovation to Clinical Translation.Journal of functional biomaterials · 2025Review
- Therapeutic potential of Withaferin A in cancer-induced muscle and cardiac wasting.Journal of ovarian research · 2025Review
- Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Accelerated Atherosclerosis in Early-Stage Breast Cancer Following Chemotherapy.JACC. Case reports · 2025Article
- Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity.Molecules (Basel, Switzerland) · 2025Review
- Cardiotoxicity induced by chemotherapy and immunotherapy in cancer treatment: a bibliometric analysis.Discover oncology · 2025Article
- The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury.Current issues in molecular biology · 2025Review
- Traditional Chinese medicine as a protective strategy against chemotherapy-induced cardiotoxicity: An overview of the literature.Journal of traditional and complementary medicine · 2025Review
- Cardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management.Cancer pathogenesis and therapy · 2025Review
- Review
- Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of cancer treatment and development of new classes of anticancer therapies have continued to revolutionize the field of oncology. New therapies including targeted agents, immunotherapies, and adoptive cell transfer have allowed for exciting survival benefit progress for patients. However, the novel nature of these therapies as well as the longer survival periods of patients receiving them has highlighted the various side effects of anticancer therapies. Cardiotoxicity has emerged as a major side effect of anticancer treatment and can present both acutely during treatment and chronically even years after treatment has been completed. This work compiles the cardiotoxic side effects of various chemotherapeutic and targeted anticancer therapies and their management.
Indexed as
Identifiers
33948350PMC8085845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.